1859141-26-6 Usage
Description
ROC-325 is a novel autophagy inhibitor that has been developed to modulate the autophagic process in cells. It is known to trigger an increase in cathepsin D (CTSD) levels, which can have significant implications for various cellular functions and responses.
Uses
Used in Pharmaceutical Industry:
ROC-325 is used as a therapeutic agent for targeting autophagy-related conditions. The expression is: ROC-325 is used as an autophagy inhibitor for modulating cellular processes and potentially treating diseases where autophagy plays a significant role.
Used in Cancer Research:
In cancer research, ROC-325 is used as a research tool to study the role of autophagy in tumor growth and progression. The expression is: ROC-325 is used as a research tool for investigating the relationship between autophagy and cancer development, as well as for identifying potential therapeutic targets in cancer treatment.
Used in Drug Delivery Systems:
ROC-325 can also be employed in the development of drug delivery systems, where it can be used to enhance the efficacy of other therapeutic agents by modulating autophagy. The expression is: ROC-325 is used as a component in drug delivery systems for improving the delivery and therapeutic outcomes of other drugs by targeting autophagy pathways.
Check Digit Verification of cas no
The CAS Registry Mumber 1859141-26-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,5,9,1,4 and 1 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1859141-26:
(9*1)+(8*8)+(7*5)+(6*9)+(5*1)+(4*4)+(3*1)+(2*2)+(1*6)=196
196 % 10 = 6
So 1859141-26-6 is a valid CAS Registry Number.
1859141-26-6Relevant articles and documents
SUBSTITUTED THIOXANTHENONE AUTOPHAGY INHIBITORS
-
, (2017/08/23)
Autophagy inhibitors useful for the treatment of cancer and other diseases are described. The autophagy inhibitors are a compound of formula: I wherein R1 is a group selected from lower alkyl, lower alkyl amide, lower alkyl ester, lower alkyl ketone, and lower alkyl ether; R2 and R3 are H or a group selected from cycloalkyl, lower alkyl, lower alkyl amide, lower alkyl ester, lower alkyl ketone, and lower alkyl ether; R4 is a heteroaryl group; and L is a —(CH2)n—X—(CH2)n— group, wherein n is 1, 2, 3, or 4, X is absent, O, S, or N—R5, wherein R5 is H or a lower alkyl group, or a pharmaceutically acceptable salt thereof.
